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Background—Open radical cystectomy (ORC) and urinary diversion in patients with bladder 
cancer (BCa) are associated with significant perioperative complication risk.
Objective—To compare perioperative complications between robot-assisted radical cystectomy 
(RARC) and ORC techniques.
Design, setting, and participants—A prospective randomized controlled trial was conducted 
during 2010 and 2013 in BCa patients scheduled for definitive treatment by radical cystectomy 
(RC), pelvic lymph node dissection (PLND), and urinary diversion. Patients were randomized to 
ORC/PLND or RARC/PLND, both with open urinary diversion. Patients were followed for 90 d 
postoperatively.
Intervention—Standard ORC or RARC with PLND; all urinary diversions were performed via 
an open approach.
Outcome measurements and statistical analysis—Primary outcomes were overall 90-d 
grade 2–5 complications defined by a modified Clavien system. Secondary outcomes included 
comparison of high-grade complications, estimated blood loss, operative time, pathologic 
outcomes, 3- and 6-mo patient-reported quality-of-life (QOL) outcomes, and total operative room 
and inpatient costs. Differences in binary outcomes were assessed with the chi-square test, with 
differences in continuous outcomes assessed by analysis of covariance with randomization group 
as covariate and, for QOL end points, baseline score.
Results and limitations—The trial enrolled 124 patients, of whom 118 were randomized and 
underwent RC/PLND. Sixty were randomized to RARC and 58 to ORC. At 90 d, grade 2–5 
complications were observed in 62% and 66% of RARC and ORC patients, respectively (95% 
confidence interval for difference, −21% to −13%; p = 0.7). The similar rates of grade 2–5 
complications at our mandated interim analysis met futility criteria; thus, early closure of the trial 
occurred. The RARC group had lower mean intraoperative blood loss (p = 0.027) but significantly 
longer operative time than the ORC group (p < 0.001). Pathologic variables including positive 
surgical margins and lymph node yields were similar. Mean hospital stay was 8 d in both arms 
(standard deviation, 3 and 5 d, respectively; p = 0.5). Three- and 6-mo QOL outcomes were 
similar between arms. Cost analysis demonstrated an advantage to ORC compared with RARC. A 
limitation is the setting at a single high-volume, referral center; our findings may not be 
generalizable to all settings.
Conclusions—This trial failed to identify a large advantage for robot-assisted techniques over 
standard open surgery for patients undergoing RC/PLND and urinary diversion. Similar 90-d 
complication rates, hospital stay, pathologic outcomes, and 3- and 6-mo QOL outcomes were 
observed regardless of surgical technique.
Patient summary—Of 118 patients with bladder cancer who underwent radical cystectomy, 
pelvic lymph node dissection, and urinary diversion, half were randomized to open surgery and 
half to robot-assisted laparoscopic surgery. We compared the rate of complications within 90 d 
after surgery for the open group versus the robotic group and found no significant difference 
between the two groups.
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1. Introduction
Primary bladder cancer (BCa) is a serious worldwide health risk [1], commonly affecting the 
elderly and smokers [2]. Radical cystectomy (RC) is the standard management of 
nonmetastatic, invasive BCa and is curative in the majority of patients with localized 
disease. Since smoking is common among patients with BCa [3,4], many present with 
significant cardiovascular, pulmonary, and renal disease. The combination of an extensive 
extirpative procedure with urinary tract reconstruction in this elderly, comorbid population 
leads to a significant perioperative morbidity and recovery time following standard open 
surgery.
Minimally invasive surgical (MIS) techniques have been rapidly adopted for the treatment 
of benign and malignant diseases, with the promise of improving perioperative morbidity 
and ease of recovery. Technical advances and the ability to use smaller incisions may ease 
recovery, limit complications, and decrease in-hospital recovery time. A more limited in-
hospital length of stay (LOS) potentially may offset the additional equipment-related costs. 
Most reported robotassisted laparoscopic RCs (RARCs) consist of a combined approach in 
which the cystectomy and pelvic lymph node dissection (PLND) are performed using the 
MIS approach, and the urinary diversion is then created through an open laparotomy 
incision [5]; however, a total incorporeal technique has gained interest [6]. Nonrandomized 
RARC series have reported lower rates of complications, improved recovery, and equivalent 
oncologic outcomes compared with open RC (ORC) outcomes [7–12]. The majority of 
RARC reports are retrospective series from single- or combined multi-institutional data sets. 
The absence of properly powered randomized studies, lack of standardized reporting 
methods, and short duration of follow-up have limited the level of evidence supporting 
whether a benefit exists for RARC versus ORC.
We have previously reported the outcomes for overall complications and LOS in this study 
[13]. In this paper, we present the detailed results of our randomized controlled surgical trial 
that assessed the perioperative 90-d complication rates, surgical and pathologic 
performance, patient-reported quality of life (QOL), and costs associated with RARC versus 
ORC, both with extracorporeal urinary diversion. We hypothesized that the minimally 
invasive approach of RARC could provide a reduction in complications, improved patient 
recovery, improved patient-reported QOL outcomes, reduced or comparable costs, and 
decreased LOS.
2. Patients and methods
2.1. Patients
BCa patients scheduled for definitive treatment by RC plus PLND and urinary diversion 
were recruited from the urology clinics at Memorial Sloan Kettering Cancer Center 
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(MSKCC) between March 2010 and March 2013. Approximately 25% of eligible patients 
agreed to enrollment and randomization. The protocol had been approved by the MSKCC 
institutional review board. All patients provided written consent prior to enrollment and 
surgery. All patients were followed ≥6 mo to provide 90-d complications and QOL data.
Eligible patients were medically cleared for RC plus PLND, aged ≥18 yr, and had BCa 
clinical stage Ta–T3/N0–3/M0. Exclusion criteria included previous pelvic radiation, 
clinical stage T4 or M1, any contraindication for Trendelenberg position, or extensive prior 
abdominal surgery. Postoperatively, all patients were placed on the identical treatment 
pathway, which is designed for a 4- to 5-d LOS.
2.2. Study design and objectives
Based on historical data [14], we expected the rate of grade 2–5 complications occurring 
within 90 d after surgery to be 50% among patients undergoing ORC. For the primary 
objective, we hypothesized that the rate of grade 2–5 complications would be 20% lower in 
absolute terms for RARC compared with ORC; that is, we expected grade 2–5 
complications to be 30% in the RARC group. A trial with an α of 5% and 80% power 
required 93 patients per arm. However, due to a mandated interim analysis to occur halfway 
through enrollment, we intended to accrue 105 patients per arm to maintain 80% power. For 
the interim analysis, we would calculate the upper bound of a one-sided 95% confidence 
interval (CI) for the difference in rate of grade 2–5 complications between surgery groups. If 
the upper bound was ≤20%, we would require stopping the trial for futility. All 
complications were graded on the MSKCC modified Clavien grading scale [14]; 
complications data were collected prospectively by unblinded MSKCC research study staff 
at the initial postoperative, 3-mo, and 6-mo follow-up visits using the institution’s standard 
reporting method for postoperative complications. All pathologic specimens were reviewed 
blinded to surgical technique.
Secondary end points included number of grade 2–5 complications, rate and number of 
grade 3–5 complications, surgical time, intraoperative blood loss, PLND nodal yield, rates 
of positive surgical margins (PSM), LOS, 3- and 6-mo patient-reported QOL outcomes, and 
total surgical and admission costs by surgery type. As a further unplanned sensitivity 
analysis, we used an analysis of covariance (ANCOVA) model to compare nodal yield 
between RARC and ORC adjusted for the extent of dissection the patient received. 
Differences in binary outcomes were assessed with the chi-square test, with differences in 
continuous outcomes assessed by ANCOVA with randomization group as the covariate and, 
for QOL end points, baseline score.
2.3. Surgical interventions
The trial was designed as an expertise-based study in which all patients randomized to open 
surgery were treated by one of four surgeons extensively experienced in ORC and urinary 
diversion. Similarly, all RARC procedures were performed by one of three surgeons with 
extensive robotic pelvic surgery experience. All urinary diversions were performed as open 
surgeries; therefore, one of the surgeons experienced in open procedures completed them 
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regardless of randomization arm. All surgeons were urologic oncology fellowship-trained 
and had a minimum of 10 yr operative experience in practice after fellowship.
Men underwent removal of the prostate if present and women underwent hysterectomy and 
bilateral salpingo-oophorectomy if those organs were present. The extent of the PLND was 
left to the discretion of the surgeon based on clinician preference and judgment (extent of 
disease, vascular disease) and determined prior to randomization. The extent of PLND was 
alterable intraoperatively based on clinical findings (vascular disease, fibrosis, adenopathy). 
Once the RC plus PLND was completed, the open urinary diversion was performed based on 
preoperative and intraoperative assessments and previous patient discussion. Bowel 
mobilization was performed robotically for all RARC patients. Incision site for diversion 
depended on type of reconstruction (periumbilical for conduit and lower midline for 
neobladder).
2.4. Randomization and treatment evaluation
Consenting patients were stratified by age (≤64 vs ≥65 yr) and American Society of 
Anesthesiologists score (1–2 vs 3–4), then randomly assigned 1:1 to undergo RARC or ORC 
using randomly permuted blocks of random length. Randomization was conducted by an 
independent office, where allocation concealment was ensured by a password-protected 
database, such that the randomization group could not be predicted prior to receiving group 
assignment and group could not be changed after randomization. The primary analysis was 
conducted according to intention-to-treat (ITT). Analyses of the main and secondary end 
points were also repeated according to actual treatment received.
2.5. Quality-of-life assessment
To assess patient-reported outcomes (PROs) of QOL, patients completed the validated 
European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life 
Questionnaire Core 30 (QLQ-C30) survey [15]. EORTC scores for each of the six functional 
domains and items are scaled from 0 to 100 using linear transformation. PROs were assessed 
at baseline (within 4 wk prior to cystectomy and after neoadjuvant chemotherapy when 
applicable) and at 3 and 6 mo postoperatively. Differences in QOL measures were assessed 
at 3 and 6 mo after cystectomy using ANCOVA, with randomization group and baseline 
score as the covariates. PROs are reported according to standards recommended by the 2010 
Consolidated Standards of Reporting Trials (CONSORT) PRO extension [16].
2.6. Cost analysis
Cost data were determined using activity-based costing. Resources consumed were assigned 
to groups of charges by category and treatment location from the general ledger, payroll, and 
purchasing and were aggregated at the patient level. Total patient costs include both direct 
costs (ie, a particular charge or service) and indirect costs (ie, an overhead cost not 
attributable to a specific charge or service).
Average total costs for the RARC and ORC arms were compared separately by urinary 
diversion type. These prices were normalized to the average Medicare reimbursement, using 
a ratio of the accounting-based prices compared with the Medicare reimbursement for that 
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service in a theoretical generic hospital. Medicare reimbursement was calculated at the 
diagnosis-related group (DRG) level according to a method developed by the Centers for 
Medicare and Medicaid Services [17]. A weighted average of DRG-level, normalized 
Medicare reimbursements was used to calculate separate multipliers for the RC with ileal 
conduit and RC with neobladder groups. The differences can thus be interpreted as the 
amount that would be reimbursed to an average hospital by Medicare if it paid differentially 
for the open or robotic-based procedures. Cost differences between open and robotic 
procedures were calculated as the difference between the average total cost for an ORC 
procedure and the average total cost for an RARC procedure. Statistical significance was 
assessed using two-sided t tests and an α of 5%. Prior to performing t tests, costs were 
logged to account for positive skew in the cost distribution and normalized as described.
3. Results
3.1. Patient disposition
Study participant flow and reasons for exclusion are shown in Figure 1. Overall, 124 
patients were accrued, 4 did not receive surgery due to progression of disease, and 2 were 
deemed ineligible after registration due to prior pelvic radiation. Of the 60 patients assigned 
to RARC, 4 refused to proceed with RARC and underwent ORC. No patient assigned to 
RARC required conversion to open surgery. All 58 patients assigned to ORC underwent 
ORC. The planned interim analysis was performed after 100 accrued patients (49 RARC, 51 
ORC) had 90-d postsurgical follow-up. The interim analysis demonstrated that the upper 
bound of the CI for the difference in rate of grade 2–5 complications (primary end point) 
between surgery groups at 3 mo was 18.6%. The trial was therefore stopped for futility 
based on the predefined criterion that the upper bound was <20%. Accrual continued until 
the interim analysis was completed, such that the final cohort for the trial included 118 
patients: 60 randomized to receive RARC and 58 to ORC.
3.2. Baseline characteristics and complications outcomes
Baseline and intraoperative characteristics of the two groups were similar (Table 1). In the 
ITT analysis, the rates of grade 2–5 perioperative complications were 62% and 66% of 
RARC and ORC patients, respectively (difference: −4%; 95% CI, −21 to 13%; p = 0.7) 
(Table 2). Overall, 21% of patients (25 of 118) experienced high-grade complications (grade 
3–5), with no differences observed between treatment groups (difference: 1.0%; 95% CI, 
−14 to 16%; p = 0.9). There were no deaths in the RARC group and a single death at 90 d in 
the ORC group (1 of 58, 1.7%). Intraoperative complications were experienced by 5% of 
patients regardless of surgical technique (p > 0.9). When patients were analyzed based on 
actual surgical procedure received rather than ITT, nearly identical results were observed 
(Table 2). The types of complications observed were similar in each arm, with infectious 
complications the most commonly identified (Table 3). The only statistically significant 
difference identified was related to wound complications, more commonly observed in 
ORC.
Based on the ITT analysis, intraoperative estimated blood loss favored the RARC group by a 
mean of 159 ml (p = 0.027) (Table 2). Operative time, however, favored the ORC group by 
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a mean time of 127 min (95% CI, 98–156; p < 0.001). Mean LOS was 8 d in both arms 
(standard deviation [SD], 3 and 5 d in RARC and ORC, respectively; p = 0.5). These 
findings were similar for both the ITT and actual-procedure-received analyses.
3.3. Pathologic outcomes
Pathologic outcomes are shown in Tables 1 and 2. Residual disease lower than pT2 was 
present on final pathologic review in 35 of 60 patients (58%) and 32 of 58 patients (55%) in 
the RARC and ORC groups, respectively; while 17 of 60 patients (28%) and 19 of 58 
patients (33%) had pT3 or higher disease (Table 1). All patients received the extent of 
PLND that had been determined preoperatively. Lymph node yield adjusted for the extent of 
the dissection demonstrated no significant differences based on technique (adjusted 
difference of 1.5; 95% CI, −2.9 to 5.9; p = 0.5). PSM rates were similar between arms 
(Table 2).
3.4. Patient-reported quality-of-life data
PRO outcomes are summarized in Table 4. Fifty-eight patients returned evaluable baseline 
surveys and 53 returned follow-up surveys at 3 and 6 mo. At baseline, measures of 
functioning were similar between arms. There were no clinical or statistical differences 
between the two arms in QOL change from baseline to 3 mo or from 3 to 6 mo in any of the 
evaluated domains (Table 4).
3.5. Cost analysis
The average normalized total operating room and inpatient costs for RARC and ORC were 
compared based on type of urinary diversion (Table 5). For RC with neobladder, RARC 
generated an average additional cost of $3920 compared with ORC (p < 0.0001). For RC 
with ileal conduit, RARC generated an average additional cost of $1740 compared with 
ORC (p < 0.05). Additional costs due to RARC were primarily related to operating room 
costs (robot, supplies, and facilities) and physician costs. For RC with ileal conduit, the 
operating room and physician costs together accounted for 98% of the additional costs due 
to RARC. For RC with neobladder, the operating room and physician costs together 
accounted for 69% of the additional costs due to RARC.
4. Discussion
The primary goal of this study was to determine whether robotic surgical techniques could 
substantially decrease the morbidity associated with RC, PLND, and urinary diversion in a 
BCa population. BCa is a smoking-related tumor [3,4], and many patients manifest cardiac, 
pulmonary, and renal dysfunction, complicating recovery after major surgery. Our 
hypothesis was that RARC would lower grade 2–5 perioperative complications by ≥20%, 
shorten hospital LOS, and improve patients’ QOL. The results of our randomized trial 
showed complication rates out to 90 d after surgery of 62% and 66% in the RARC and ORC 
arms, respectively, using an ITT analysis. At the mandated interim analysis of this protocol, 
the similarity in complication rates met the trial’s predetermined futility criteria and led to 
the early closure of the trial. The validity of the results of this trial is partly dependent on 
whether the outcomes of our primary end point (90-d complications) were comparable to 
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those reported in large, expert ORC and RARC series. Comparative evaluation of 
complications between surgical series poses many challenges related to variations in the 
method, consistency, and documentation of data reporting. Documented variations in the 
quality of surgical complications reporting are found across surgical disciplines [18]. Our 
trial design collected data prospectively, using a defined, previously published 
complications grading system [14]; several ORC and RARC series have used a similar 
grading system for complications reporting [8,12,14]. In a group of 1142 consecutive BCa 
patients managed by standard ORC and urinary diversion, the perioperative 90-d 
complication rate was 64% [14], nearly identical to that observed in our randomized ORC 
arm. Most common complications were infectious (25%), gastrointestinal (29%), and wound 
related (15%) [14].
Rates of complications after RARC have varied greatly in published series and likely reflect 
variations in reporting methods and patient selection [7–9,12,19]. The observed 62% 
complication rate in our RARC arm was similar to that reported in one of the largest single-
institution series of RARC, in which the overall 90-d complication rate was 80% [12]. The 
majority of complications identified after ORC or RARC are low grade. We observed a 21% 
overall high-grade complication rate in the current trial, including 21% and 22% for RARC 
and ORC, respectively. Reported high-grade complication rates in RARC-treated patients 
have ranged from 19% in a 939-patient, RARC, multi-institutional series to 35% in the 
largest single-center report [8,12]. We have previously reported a 2.7% 90-d mortality rate 
in 1142 consecutive ORC patients [14]. The current trial observed no deaths in the RARC 
group and a single mortality at 90 d in the ORC group (1 of 58, 1.7%). The International 
Robotic Cystectomy Consortium (IRCC) reported a 4.2% 90-d mortality in 939 patients [8].
Hospital LOS following RC and urinary diversion is associated with the extent and severity 
of complications encountered [20]. Several RARC reports have suggested a benefit in LOS 
compared with ORC [10,21], whereas others have not [22,23]. The IRCC data set of 939 
RARC patients demonstrated a median LOS of 8 d [8]. Our randomized trial displayed a 
similar median LOS of 8 d for both RARC and ORC, and thus showed no advantage for the 
robotic technique. LOS after RC is a function of recovery from both the extirpative and 
reconstructive parts of the operation. Despite a uniform postoperative pathway that allowed 
for early feeding, mobilization, and discharge by day 4 or 5 regardless of diversion type, no 
benefit in LOS was observed in the RARC group; however, we did not directly quantify 
differences in intermediate measures of recovery, such as time to return of bowel function or 
postoperative pain.
Measures of surgical quality for RC include PSM rates and lymph node yields, both of 
which have implications for oncologic outcomes. A PSM affects local recurrence, doubles 
the metastatic progression risk, and adversely affects cancer-specific survival [24,25]. In two 
large ORC series comprising 3180 patients, PSM were identified in 0% of organ-confined 
tumors (pT2N0 or lower) and 3–9% of patients with extravesical disease [25,26]. In 
contrast, the 939-patient international RARC study reported an overall PSM rate of 6.8% in 
513 patients, 1.5% for organ-confined tumors, and 17% for extravesical tumors, including 
8.3% for pT3 and 39% for pT4 tumors [8]. In general, higher lymph node yield is associated 
with improved disease-specific survival and overall survival [27–29]. Several reports have 
Bochner et al. Page 8
Eur Urol. Author manuscript; available in PMC 2016 June 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
demonstrated that extended PLND is feasible using robotic techniques and that with 
increasing experience, similar lymph node yields may be obtained [12,22,30]. We confirm 
the previously noted observations [30–32] that RARC plus extended PLND is feasible in 
most patients and has similar lymph node yields as the open procedure, but requires 
substantial time to complete. Others have demonstrated that increased volume and greater 
experience of RARC in the surgeon is positively associated with the completion of a PLND 
and with increased lymph node yield [33].
RC and urinary diversion can significantly alter QOL due to the required surgical recovery 
related to the associated complications and catabolic state induced by the trauma of 
treatment. A major purported benefit of MIS techniques is to ease the process of recovery, 
leading to improved QOL. Analysis of PRO in this study showed similar findings between 
ORC versus RARC at 3 or 6 mo after surgery. Our results are similar to those reported from 
a large, multicenter, randomized study of minimally invasive versus open colectomy for 
colorectal cancer, which showed no difference in QOL at 2 mo [34]. Unlike the latter study 
that showed a small difference in global rating scale favoring laparoscopic surgery at 2 wk, 
we did not evaluate PRO before 3 mo, which limits our ability to detect differences in very 
short-term QOL. Cost analyses have previously suggested a benefit in favor of RARC over 
ORC [35], whereas others have not [36]. Our study demonstrated increased total costs 
(operating room and inpatient) for RARC procedures whether the diversion was a conduit or 
neobladder, although the extent of the differences appeared lower for neobladder patients. 
The lack of difference in hospital LOS, the added equipment costs, and longer operating 
room times contributed to the greater costs associated with robotic procedures.
Limitations of this study include that it was completed at a single high-volume referral 
center, and the surgeons in this trial were highly experienced in performing ORC and 
RARC, respectively; thus these results may not be completely generalizable to surgeons less 
experienced in the RC/PLND procedure. As with most centers worldwide, our experience 
with ORC is significantly greater than with RARC. Although the surgeons using robotic 
techniques in this trial have performed thousands of robotic pelvic procedures, our results 
with RARC may improve as greater experience accumulates; however, the reported 
outcomes for our RARC arm compare favorably with the largest, multiyear RARC series 
reported to date [12]. Since our study was designed to detect a 20% difference in grade 2–5 
complications, our negative results do not exclude the possibility that robotic techniques 
may reduce complication rates by 10–15%, which would not be clinically insignificant; 
however, we found no evidence of such a difference. Additionally, a lower rate of positive 
lymph nodes in our study population suggests that the distribution of patients enrolled had a 
more favorable oncologic outcome compared with previous reported ORC series.
5. Conclusions
This prospective, randomized trial observed 62% and 66% 90-d perioperative rates of grade 
2–5 complications in RARC- and ORC-treated patients, respectively, thus excluding a large 
benefit in perioperative morbidity for RARC over ORC. While some surgical parameters 
were improved using RARC, others were not favorably enhanced and use of RARC did not 
result in a shorter LOS. Although RARC did provide similar pathologic outcomes compared 
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with ORC, costs and QOL measures at 3 and 6 mo postoperatively failed to demonstrate a 
benefit of RARC over conventional open surgery. While robotic technology holds promise 
in improving patient outcomes, this randomized study failed to confirm previously reported 
patient benefits.
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Take-home message
This randomized controlled trial demonstrated no advantage for robot-assisted radical 
cystectomy (RARC) with pelvic lymph node dissection (PLND) over standard open 
radical cystectomy with PLND (both with open diversion) with respect to 90-d 
complications, length of stay, 3- and 6-mo quality of life, or costs. While some surgical 
parameters were more favorable for RARC, others were not.
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Fig. 1. Randomization and follow-up of study patients
ORC = open radical cystectomy; RARC = robot-assisted laparoscopic radical cystectomy.
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Table 1
Participant characteristics
Robotic (n = 60) Open (n = 58)
Baseline
Age, yr, median (IQR) 66 (60–71) 65 (58–69)
Male sex, n (%) 51 (85) 42 (72)
Body mass index, kg/m2, median (IQR) 27.9 (24.7–31.0) 29.0 (26.3–33.7)
ASA score, n (%)
 2 17 (28) 12 (21)
 3 42 (70) 43 (74)
 4 1 (1.7) 3 (5.2)
Prior bacillus Calmette-Guérin therapy, n (%) 30 (50) 18 (31)
Clinical stage, n (%) *
 Tis 8 (14) 2 (3.5)
 Ta 1 (1.7) 3 (5.3)
 T1 21 (36) 19 (33)
 T2 24 (41) 28 (49)
 T3 4 (6.8) 5 (8.8)
 T4 1 (1.7) 0 (0)
Neoadjuvant chemotherapy, n (%) 19 (32) 26 (45)
Intraoperative
Urinary diversion type, n (%)
 Ileal conduit 27 (45) 23 (40)
 Neobladder 33 (55) 32 (55)
 Continent cutaneous 0 (0) 3 (5.2)
Level of lymph node dissection, n (%)
 External iliac 0 (0) 4 (6.9)
 Common iliac 13 (22) 26 (45)
 Aortic bifurcation 33 (55) 20 (34)
 Inferior mesenteric artery 14 (23) 8 (14)
Received assigned surgery 56 (93.3) 58 (100)
Pathology from final cystectomy specimen
Histology, n (%)
 Adenocarcinoma 0 (0) 1 (1.7)
 Squamous cell carcinoma 1 (1.7) 1 (1.7)
 Small cell carcinoma 1 (1.7) 1 (1.7)
 Small cell plus transitional cell carcinoma 1 (1.7) 0 (0)
 Transitional cell carcinoma 57 (95) 55 (95)
Pathologic stage, n (%)
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Robotic (n = 60) Open (n = 58)
 T0 13 (22) 7 (12)
 Tis 14 (23) 11 (19)
 Ta 1 (1.7) 3 (5.2)
 T1 7 (12) 11 (19)
 T2 8 (13) 7 (12)
 T3 12 (20) 15 (26)
 T4 5 (8.3) 4 (6.9)
ASA = American Society of Anesthesiologists; IQR = interquartile range. Adapted from Bochner et al [13].
*
Missing data for one participant in each of the two arms.
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